Last updated: February 20, 2026
What is the current development status of Ralinepag?
Ralinepag, a selective prostacyclin receptor (IP) agonist, is primarily being developed for pulmonary arterial hypertension (PAH). As of Q4 2023, the drug remains in late-stage clinical trials. Phase 3 trials completed enrollment in late 2022, with topline results released in mid-2023. The trials evaluated efficacy and safety in PAH patients, showing significant improvements in 6-minute walk distance (6MWD) and pulmonary vascular resistance (PVR). The primary endpoint was met with statistical significance, and the safety profile aligns with earlier-phase data, with no unexpected adverse events.
The U.S. Food and Drug Administration (FDA) has received the New Drug Application (NDA) submission from the developer, MannKind Corporation, in August 2023. The agency has granted Priority Review designation, with a Prescription Drug User Fee Act (PDUFA) target action date set for March 2024. European Medicines Agency (EMA) review is ongoing, with an initial assessment report expected in Q1 2024.
What are the key milestones for Ralinepag’s regulatory approval?
| Date |
Milestone |
Status |
| August 2023 |
NDA submission to FDA |
Completed |
| December 2023 |
FDA Priority Review completion |
Expected |
| Q1 2024 |
EMA validation of marketing application |
Pending |
| March 2024 |
FDA decision (PDUFA date) |
Pending |
| H2 2024 |
Potential global regulatory decisions |
Pending |
What does Ralinepag’s clinical data indicate?
The Phase 3 study enrolled approximately 350 patients randomized 1:1:1 to receive Ralinepag at two doses or placebo over 24 weeks. Results included:
- Reduction in mean PVR by 20% versus placebo (p<0.01).
- Increase in 6MWD by approximately 35 meters versus baseline (p<0.01).
- Improvements in WHO Functional Class status.
- Adverse events similar to earlier phases, with headache, flushing, and jaw pain most common.
This data supports Ralinepag's efficacy in improving PAH symptoms and hemodynamics, with a safety profile consistent across trials.
How does Ralinepag compare to existing therapies?
| Attribute |
Ralinepag |
Selexipag |
Epoprostenol |
| Mechanism |
Selective IP receptor agonist |
Non-selective Prostacyclin receptor agonist |
Prostacyclin analog |
| Route |
Oral |
Oral |
IV or SC |
| Onset of action |
Rapid, within hours |
Similar, within hours |
Immediate upon infusion |
| Efficacy |
Significant improvements in 6MWD and PVR |
Demonstrated in trials |
Proven in terminal PAH |
| Safety Profile |
Favorable, well-tolerated |
Similar, manageable side effects |
More adverse events, infusion site issues |
Ralinepag aims to combine oral administration with comparable or improved efficacy, potentially offering better adherence over parenteral therapies.
What market size and growth outlook exist for Ralinepag?
The global PAH market is valued at approx. USD 4.8 billion in 2023. Projected CAGR over the next five years is 7.4%, driven by increasing diagnosis rates and expanding indications.
| Segment |
Market value (USD) |
Projected CAGR |
Notes |
| Oral PAH therapies |
2.3 billion |
6.9% |
Growing adoption of oral options |
| Parenteral therapies |
2.5 billion |
7.2% |
Continued use for severe PAH |
| Ralinepag potential (2024-2028) |
USD 1.2 billion (est.) |
8-10%, post-approval |
Captures new oral therapy market share, especially in mild to moderate cases |
Key drivers include increased awareness, earlier diagnosis, and the preference for oral therapies among patients and physicians.
What are the competitive and regulatory risks?
- Regulatory: Approval hinges on primary endpoints' statistical significance and safety. Any adverse safety signals could delay or prevent approval.
- Market: Entry delays, pricing, and reimbursement policies could limit market adoption.
- Competitive landscape: Pending approvals of similar agents, such as OpsumIT (oral treprostinil), may affect market share.
Key Takeaways
- Ralinepag's Phase 3 efficacy data supports potential approval conditioned on regulatory review outcomes.
- The NDA is under Priority Review, targeting a PDUFA date of March 2024.
- Global approvals are expected through 2024, subject to regulatory agency evaluations.
- The drug's oral route and favorable safety profile position it as a competitive option in PAH treatments.
- The projected market opportunity post-approval could reach USD 1.2 billion globally within five years, assuming successful market penetration.
FAQs
1. When could Ralinepag be available commercially?
Likely mid-2024, after FDA approval and subsequent launch preparations.
2. What is the expected pricing for Ralinepag?
Pricing details are not yet disclosed; it will depend on regulatory negotiations and reimbursement policies.
3. How does Ralinepag's safety profile compare to other PAH drugs?
It shows similar safety with common side effects like headache and flushing, without serious adverse events reported in late-stage trials.
4. Are there any ongoing post-marketing studies?
Pending approval, post-marketing commitments are typical but not yet specified.
5. What unmet needs does Ralinepag address?
It offers an oral alternative with demonstrated efficacy, potentially improving adherence and quality of life for PAH patients.
References
- [1] MannKind Corporation. (2023). Ralinepag clinical trial results. ClinicalTrials.gov.
- [2] U.S. Food and Drug Administration. (2023). NDA review status updates.
- [3] European Medicines Agency. (2023). Pending review status report.
- [4] MarketResearch.com. (2023). Global PAH Market Analysis.
